ACLY and atherosclerosis: Using genetic and pharmacologic methods to suppress ACL in vitro, and by testing the effects of ETC-1002 in a novel APOE/AMPK β1 double-knockout (DKO) mouse model, we establish ACL inhibition as the primary mechanism leading to reduced LDL-C and atherosclerosis.